Categories: BionicNews

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings

Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the Company as soon as it becomes aware of it.

Pixium draws investors’ attention to the fact that, given the price offered by the prospective buyer and the Company’s level of indebtedness, the sale proceeds received in the event of a favourable decision by the Commercial Court will not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision  

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

 

Attachment

Staff

Recent Posts

Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design

MILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP),…

4 hours ago

AffableBPM Graduates from 2025 Creative Destruction Lab (CDL) Program

Accelerating AI-Powered Automation for Healthcare Operations SEATTLE, June 16, 2025 /PRNewswire/ -- AffableBPM is proud…

4 hours ago

Waystar Appoints Aashima Gupta and Michael Roman to Board of Directors

New directors bring deep expertise in AI innovation, healthcare, and enterprise growth LEHI, Utah and…

10 hours ago

Occupational Health Market to Reach USD 8,453.96 million By 2032, Growing At An 6.50% CAGR – Credence Research

PUNE, India, June 16, 2025 /PRNewswire/ -- The global Occupational Health Market was valued at USD…

10 hours ago

AdventHealth Tampa first in region to perform colorectal surgery using da Vinci SP robot

TAMPA, Fla., June 16, 2025 /PRNewswire/ -- AdventHealth Tampa is now the first hospital in…

10 hours ago

AARP Services Announces New AARP Member Benefits Launching This Summer

WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the…

10 hours ago